KPV

Background

KPV (Lysine–Proline–Valine; H‑Lys‑Pro‑Val‑OH) is a C‑terminal tripeptide fragment of α‑melanocyte‑stimulating hormone (α‑MSH), an endogenous peptide derived from proopiomelanocortin (POMC).[12] α‑MSH and its fragments, including KPV and the longer KPV‑containing sequence Lys‑Pro‑Val‑Gly‑Lys‑Lys‑Arg (KP‑derivatives), have long been recognized for anti‑inflammatory and immunomodulatory properties in skin and mucosal tissues.[12][14]

KPV itself is not a hormone in the classical sense but a minimal pharmacophore retaining much of the anti‑inflammatory activity of the parent α‑MSH while being substantially smaller and more amenable to chemical modification and oral or topical delivery.[12][14] Early work in intestinal epithelial and immune cell models identified KPV as a candidate therapeutic for inflammatory bowel disease (IBD) and related mucosal inflammatory conditions.[12] Subsequent formulation research has explored nanoparticle and prodrug strategies to improve its stability and targeted delivery to the colon.[11][14]

KPV is currently an experimental peptide; there are no approved medicinal products containing KPV as an active pharmaceutical ingredient in the US or EU.

Mechanism of action

Relationship to α‑MSH and melanocortin receptors

α‑MSH exerts its anti‑inflammatory effects primarily via melanocortin receptors (MC1R, MC3R, MC4R, MC5R), leading to reduced NF‑κB activation and downregulation of pro‑inflammatory cytokines such as TNF‑α, IL‑1β, and IL‑6.[12] KPV is the C‑terminal tripeptide of α‑MSH and preserves key structural features necessary for anti‑inflammatory signaling, though with reduced potency and receptor selectivity relative to the full‑length peptide.[12][14]

In intestinal epithelial cells and immune cells, KPV has been shown to inhibit NF‑κB activation and reduce expression of TNF‑α, IL‑6, and other pro‑inflammatory mediators, mirroring α‑MSH effects.[12] These actions are consistent with melanocortin receptor–mediated signaling, although KPV may also exert receptor‑independent effects at higher concentrations.[12]

Cellular uptake via PepT1

A notable feature of KPV is its transport via PepT1 (SLC15A1), a proton‑coupled oligopeptide transporter expressed in the small intestine and colon and upregulated in inflamed intestinal mucosa.[12]

In a key mechanistic study, Wang et al. (2007) demonstrated that:

• KPV uptake into Caco‑2 intestinal epithelial cells and immune cells is PepT1‑dependent, as shown by inhibition with the dipeptide Gly‑Gly and other PepT1 substrates.[12]
• Overexpression of PepT1 enhanced KPV uptake and its anti‑inflammatory effects.
• KPV reduced NF‑κB activation and cytokine production in PepT1‑expressing cells but had minimal effect when PepT1 was absent or inhibited.[12]

These findings support a model in which KPV is transported into target cells by PepT1, then modulates intracellular inflammatory signaling.

Structural modification and pharmacokinetics

KPV, like many small peptides, is susceptible to rapid degradation and renal clearance. Shinde et al. (2018) used “reductive glycoalkylation” to replace the lysine side‑chain amine in KPV with a dihydroxylated piperidine, generating glycosylated analogues with improved stability.[14] These modified KPV derivatives maintained anti‑inflammatory activity in vitro and exhibited enhanced resistance to proteolysis, illustrating a strategy to improve pharmacokinetic properties.[14]

Evidence summary

Intestinal inflammation and IBD models

1. PepT1‑mediated uptake and colitis models (Wang et al., 2007)

• Study type: In vitro and in vivo preclinical study.[12]
• Models: Caco‑2 cells, immune cells; dextran sulfate sodium (DSS) and trinitrobenzenesulfonic acid (TNBS) colitis in mice.
• Key findings:
  • KPV was taken up via PepT1 and reduced NF‑κB activation and cytokine expression in PepT1‑expressing cells.[12]
  • Oral KPV administration reduced the incidence and severity of DSS‑ and TNBS‑induced colitis, with decreased colonic TNF‑α and other inflammatory markers.[12]
• Sample sizes: Typical experimental groups in the DSS/TNBS mouse studies were modest (on the order of n≈6–10 per group); exact numbers vary by experiment but were adequate for initial efficacy signals.[12]

The authors concluded that KPV “might be a new therapeutic agent for IBD,” while emphasizing that data were limited to animal models and in vitro systems.[12]

2. HA‑functionalized nanoparticles for oral KPV (Liu et al., 2017)

• Study type: Preclinical formulation and efficacy study using hyaluronic acid‑functionalized nanoparticles (HA‑KPV‑NPs) with a chitosan/alginate hydrogel for colon‑targeted delivery.[11]
• Model: DSS‑induced ulcerative colitis in mice.
• Key findings:
  • HA‑KPV‑NP/hydrogel enabled targeted release in the colonic lumen and penetration into inflamed tissue.[11]
  • Compared with KPV‑NP/hydrogel without HA, HA‑KPV‑NP/hydrogel more effectively prevented mucosal damage, accelerated mucosal healing, and downregulated TNF‑α and other inflammatory cytokines.[11]
  • Histology scores, colon length, and clinical indices (body weight, stool consistency, bleeding) were significantly improved versus untreated or non‑targeted control groups.[11]

These data support the concept that targeted nanoparticle delivery of KPV can enhance its local therapeutic effect in colitis models.

Other models

The literature also includes in vitro studies examining KPV analogs and structure–activity relationships for anti‑inflammatory effects, but robust in vivo data beyond intestinal inflammation are limited.[14] There are no published randomized controlled trials or large‑animal studies specifically evaluating KPV as a systemic therapeutic.

Human data

As of the latest available reports, no human clinical trials of KPV as a therapeutic agent have been published, and KPV does not appear in major clinical trial registries as a standalone investigational drug. Available evidence is therefore preclinical only, and any extrapolation to human efficacy or safety remains speculative.

Clinical and research uses

Investigational and preclinical uses

Current research focuses mainly on:

• Inflammatory bowel disease / ulcerative colitis

  • As a locally active anti‑inflammatory tripeptide delivered orally with targeted release to the colon.[11][12]
  • Intended to reduce epithelial and immune cell inflammation via PepT1‑mediated uptake and NF‑κB inhibition.[12]

• Peptide engineering and delivery science

  • KPV serves as a model tripeptide for assessing prodrug and glycoalkylation strategies to enhance oral bioavailability and stability.[14]
  • HA‑functionalized nanoparticles and mucoadhesive hydrogels are being explored to optimize local delivery in the gut.[11]

• Melanocortin biology

  • As a minimal α‑MSH fragment, KPV is used experimentally to dissect sequence determinants of anti‑inflammatory activity within the melanocortin system.[12][14]

Off‑label or compounded use

KPV has been discussed in non‑peer‑reviewed contexts as a compounded or cosmetic peptide (e.g., topical or subcutaneous use), but such applications are not supported by controlled clinical data and are not described in major scientific publications. No standardized indications or treatment protocols exist.

Dosing context

KPV is not an approved drug; doses below are research‑context only and must not be interpreted as clinical recommendations.

Oral dosing in animal models

• Wang et al. (2007) administered KPV orally in mice with DSS‑ or TNBS‑induced colitis.[12] Doses were typically in the low‑to‑moderate mg/kg range (exact regimen described in the article), given once or multiple times daily during the induction and/or progression of colitis.[12]

• Liu et al. (2017) used HA‑KPV‑NPs encapsulated in a hydrogel administered orally to mice with DSS colitis.[11] The KPV amount per dose was calibrated to achieve therapeutic concentrations in the colon; again, dosing was in the mg/kg range, with schedules aligned to the DSS exposure period.[11]

Formulation considerations

• Free peptide: Rapid degradation and limited stability in the gastrointestinal tract are expected, constraining oral bioavailability.[14]
• Nanoparticle / hydrogel systems: Designed to protect KPV from degradation, release it in the colon, and enhance mucosal residence time.[11]
• Glycoalkylated analogues: Chemically modified to reduce proteolysis and potentially enable more sustained systemic exposure.[14]

No human pharmacokinetic, dose‑finding, or maximum tolerated dose studies have been reported.

Safety profile

Preclinical safety observations

In the available mouse colitis studies:

• Oral KPV (free peptide) did not produce notable toxicity at the doses tested; animals tolerated treatment without obvious adverse clinical signs beyond those attributable to colitis itself.[12]
• HA‑KPV‑NP/hydrogel formulations similarly did not show overt systemic toxicity in mice, with body weight and general behavior comparable or improved relative to untreated colitic controls, reflecting disease mitigation rather than drug‑related toxicity.[11]

Standard toxicology endpoints (e.g., detailed organ histopathology outside the gut, genotoxicity, reproductive toxicity) were not systematically evaluated. Long‑term safety data are absent.

Potential and theoretical risks

Based on peptide class and mechanism, potential risks include:

• Immune or hypersensitivity reactions: As a small peptide, KPV is less likely to be strongly immunogenic, but repeated administration or certain formulations (e.g., nanoparticle carriers) could theoretically elicit immune responses.
• Off‑target melanocortin effects: High systemic exposures could, in principle, interact with melanocortin receptors, potentially affecting pigmentation, energy balance, or cardiovascular parameters, although this has not been demonstrated for KPV in vivo.[12]
• Altered gut microbiota and barrier function: Chronic modulation of intestinal inflammation and epithelial transport might influence microbiome composition; no data are available.

Human adverse effects

There are no systematic human safety data for KPV. Consequently, no adverse effect profile, contraindications, or drug–drug interaction patterns can be defined based on clinical evidence.

Regulatory status

• United States (FDA)

  • KPV is not approved by the US Food and Drug Administration as a drug, biologic, or medical device.
  • It does not appear in FDA drug labels or approval databases as an active ingredient.
  • There are no publicly registered phase 1–3 trials of KPV as a therapeutic agent in ClinicalTrials.gov, indicating that development remains at the preclinical or very early translational stage.

• European Union (EMA and national agencies)

  • KPV is not authorized as a medicinal product by the European Medicines Agency.
  • It is not listed in major EU centralized procedure approvals and has no known marketing authorization status in EU member states.

• Regulatory classification

  • Currently, KPV is best characterized as a preclinical investigational peptide used in academic and early translational research, mainly as a tool compound and proof‑of‑concept anti‑inflammatory agent in animal models.
  • Any compounding or cosmetic use occurs outside formal regulatory approval pathways and is not supported by regulatory guidance or clinical trial data.

Given the absence of human trials and regulatory submissions, KPV should be regarded as experimental with uncertain clinical benefit–risk profile pending further research.